Introduction
Autoimmune encephalitides are a group of syndromes that may present with subacute onset of disorientation, personality changes, memory loss and most prominently seizures. Earlier reports of this entity were from patients with paraneoplastic limbic encephalitis, however autoimmune etiologies have also been described in patients with non-paraneoplastic encephalitis [1] .
The Alpha 3 ganglionic acetylcholine receptor autoantibody (a3-AChR Ab) mainly causes autoimmune dysautonomia that is either subacute or insidious in onset. A direct relationship betweenantibody titer and severity of dysautonomia occurs in both experimental animals and patients [2] . Most of these cases have been paraneoplastic (mainly adenocarcinomas) however a few cases have been linked to other autoimmune disorders such as systemic lupus erythematosus (SLE) and Sjogren's syndrome. Patients who are seropositive for a3-AChR Ab may present with less common neurological manifestations such as peripheral neuropathies, encephalopathy and subacute neuropsychiatric presentations.
This report presents a unique case of refractory new-onset status epilepticus associated with a3-AChR antibody which responded to immunotherapy.
Case illustration
An 82-year-old lady presented to the emergency room with a one day history of left-sided weakness and confusion. She had amedical history of small cell lung cancer with resection in 2011 and currently in remission. While in the emergency room, she was witnessed to have a 1 min generalized tonic-clonic seizure with left-sided gaze deviation. The convulsions were aborted with 2 mg of intravenous (IV) lorazepam but she continued to have forced eye deviation to the left and residual left arm weakness. Electroencephalogram (EEG) with video monitoring showed nonconvulsive status epilepticus (NCSE) originating from the right temporal region. She was treated with IV lorazepam, and then subsequently levetiracetam and lacosamide were administered which successfully terminated the NCSE though there was residual lateralized periodic discharges (LPDs) over the right temporal region (Fig. 1A ).
An MRI of the brain did not show any significant T2 signal changes or enhancement. A lumbar puncture was performed and the cerebrospinal fluid (CSF) was remarkable for 7/high power field nucleated cells (84% lymphocytes) and 94 mg/dL of protein.
CSF gram stain and polymerase chain reaction for Herpes simplex virus were negative. Her serum was remarkable for an elevated erythrocyte sedimentation rate (83 mm/h) and elevated C-reactive protein (56.2 mg/L). Serum autoimmune workup revealed a positive anti-nuclear antibody (1:80 titer). Serum electrophoresis with immunofixation showed IgG lambda band in low concentration. Further paraneoplastic work-up including anti-glutamic acid decarboxylase, N-methyl-D-aspartate, voltage-gated potassium channel, anti-thyroid peroxidase and thyroglobulin antibodies were negative. Her serum levels of ganglionic acetylcholine receptor antibody against a3 subunit titer returned positive at 0.11 nmol/L (normal <0.02 nmol/L). Other radiological investigations for occult malignancies were negative.
Her clinical improvement was very gradual and by day 10, the patient had recovered most of her strength but would occasionallyhave fluctuations in mentation. Her EEG continued to show right hemisphere LPDs without evolution. On day 21, she developed recurrent clinical seizures, which were treated with higher doses of her previous AEDs (lacosamide 200 mg twice daily; levetiracetam 1000 mg twice daily). However, on hospital day 30 she developed NCSE over right temporal region which was again aborted with IV lorazepam and phenytoin (loading dose of 20 mg/kg; subsequently 300 mg daily) was added to her previous AED regimen. Due to her fluctuating levels of consciousness, inability to follow commands, unremitting right temporal LPDs on EEG resistant to AED's (Fig. 1B) and concern for autoimmune encephalitis, she was started on a 5 day course of IV methylprednisolone, followed by oral prednisone. Five days after the initiation of steroids, the LPDs disappeared and were replaced by focal discharges over the right temporoparietal region (Fig. 1C) . The patient began to improve a few days after initiating treatment and after a week, she regained full strength in all her extremities and was able to follow simple commands. At the time of discharge, she had near complete cognitive recovery and normal strength in her extremities.
Discussion
Our patient presented with new onset refractory NCSE of autoimmune etiology that was associated with a3-AChR Ab. A retrospective study for neurological, oncological and serological associations of a3-AChR Ab seropositivity conducted at Mayo clinic [2] showed that neurological presentations were directly proportional to antibody titers. Antibody values of 1.00 nmol/L or higher were associated with symptoms of dysautonomia. Medium antibody titers of 0.10-0.99 presented with more diverse neurological symptoms, which included peripheral neuropathies (36%), dysautonomia (20%, usually limited) and encephalopathy (30%). Low antibody titers of 0.03-0.09 presented mostly with nonautoimmune neurological disorders or no neurological disorder. Malignancies, either active or by history have been identified as the most common etiology associated with seropositive a3-AChR Ab.
Adenocarcinomas are the most common to be identified.
There has been only one previously reported case of seizures secondary to a3-AChR Ab autoimmune disease, but this patient did not respond to immunotherapy with intravenous steroids and IVIG [3] . Even with antibody titers in the low-medium range, our patient presented with new onset refractory status epilepticus that did not respond to standard AED treatment and eventually responded (clinically and electrographically) to steroids. Interestingly, our patient did not have any clinical manifestations of dysautonomia but this may have been due to the moderate antibody titers present.
No single specific pattern on EEG has been reported to coincide with limbic encephalitis (LE) [4] . Our patient had multiple, focal recurrent seizures and NCSE as well as prolonged focal LPDs with alteration of consciousness despite aggressive AED treatment. Her clinical course and CSF findings were highly suspicion for autoimmune-mediated epilepsy. Eventual treatment with immunosuppressant led to improvement in patient's clinical condition. To our knowledge, no EEG changes have been reported in patients associated with a3-AChR Ab LE in the literature.
Conclusion
This is the first reported case of new onset refractory status epilepticus linked to a3-AChR Ab that responded to immunotherapy with steroids. A combination of oral steroids and AEDs may be beneficial in the long-term management of these patients. The diagnosis of autoimmune disease in new onset epilepsy or status epilepticus requires a high level of suspicion. Work-up for autoimmune etiology should be considered in patients with recurrent or intractable seizures, AED resistance, personal or family history of autoimmune disease and history of cancer. Further insight on the duration of immunotherapy is required for prognostication and improved outcome in these patients.
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